Company: PSTV
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001193125-25-050390
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

Plus Therapeutics, Inc. (the “ Company”) has announced that the Nasdaq Stock Market LLC (“ Nasdaq”) has confirmed in a letter dated March 7, 2025 (the “ Letter”) that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “ Minimum Stockholders’ Equity Requirement”).

As previously disclosed by the Company in aCurrent Report on Form 8-Kfiled on November 1, 2024, Nasdaq had provided the Company until March 4, 2025, to notify Nasdaq that the Company was in compliance with the Minimum Stockholders’ Equity Requirement. The Company regained compliance with the Minimum Stockholders’ Equity Requirement in connection with the private placement (the “ Private Placement”) disclosed by the Company in itsCurrent Report on Form 8-Kfiled on March 4, 2025.

Based on the receipt of the Letter, the funds from the Company’s previously disclosed Private Placement are being released from escrow.

Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until March 7, 2026. If the Nasdaq Listing Qualifications staff (the “ Staff”) finds the Company again out of compliance with the Minimum Stockholders’ Equity Requirement before that date, the Company would not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff would not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor would the Company be afforded an applicable cure or compliance period. Instead, the Staff would issue a “ Delist Determination Letter” and the Company would have an opportunity to request a Nasdaq hearing panel regarding its continued listing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                            PLUS THERAPEUTICS, INC.                               
  Date: March 10, 2025      By:                          /s/ Andrew Sims          
                            Name:                        Andrew Sims              
                            Title:                       Chief Financial Officer